Last reviewed · How we verify

Diiodoquin (diiodohydroxyquinoline)

FDA-approved active ✓ Verified May 2026 Quality 20/100

Diiodoquin (generic name: diiodohydroxyquinoline) is a diiodohydroxyquinoline drug. It is currently FDA-approved for Amebic infection.

Diiodoquin is a small molecule with the chemical name diiodohydroxyquinoline, used in the treatment of amoebiasis. It is a quinoline derivative with various synonyms, including DIIODOHIDROXIQUINOLEINA and DIIODOHYDROXYQUINOLINE.

At a glance

Generic namediiodohydroxyquinoline
Drug classdiiodohydroxyquinoline
TargetMitogen-activated protein kinase 1
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Diiodoquin

What is Diiodoquin?

Diiodoquin (diiodohydroxyquinoline) is a diiodohydroxyquinoline drug, indicated for Amebic infection.

What is Diiodoquin used for?

Diiodoquin is indicated for Amebic infection.

What is the generic name of Diiodoquin?

diiodohydroxyquinoline is the generic (nonproprietary) name of Diiodoquin.

What drug class is Diiodoquin in?

Diiodoquin belongs to the diiodohydroxyquinoline class. See all diiodohydroxyquinoline drugs at /class/diiodohydroxyquinoline.

What development phase is Diiodoquin in?

Diiodoquin is FDA-approved (marketed).

What does Diiodoquin target?

Diiodoquin targets Mitogen-activated protein kinase 1 and is a diiodohydroxyquinoline.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing